- Home
- RCUS vs OMCL Comparison
RCUS vs OMCL Comparison
Compare RCUS & OMCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCUS
- OMCL
- Stock Information
- Founded
- RCUS 2015
- OMCL 1992
- Country
- RCUS United States
- OMCL United States
- Employees
- RCUS N/A
- OMCL N/A
- Industry
- RCUS Biotechnology: Pharmaceutical Preparations
- OMCL Computer Manufacturing
- Sector
- RCUS Health Care
- OMCL Technology
- Exchange
- RCUS Nasdaq
- OMCL Nasdaq
- Market Cap
- RCUS 1.2B
- OMCL 1.5B
- IPO Year
- RCUS 2018
- OMCL 2001
- Fundamental
- Price
- RCUS $12.03
- OMCL $31.18
- Analyst Decision
- RCUS Buy
- OMCL Buy
- Analyst Count
- RCUS 8
- OMCL 7
- Target Price
- RCUS $20.71
- OMCL $46.71
- AVG Volume (30 Days)
- RCUS 711.9K
- OMCL 470.2K
- Earning Date
- RCUS 11-05-2025
- OMCL 10-29-2025
- Dividend Yield
- RCUS N/A
- OMCL N/A
- EPS Growth
- RCUS N/A
- OMCL N/A
- EPS
- RCUS N/A
- OMCL 0.49
- Revenue
- RCUS $262,000,000.00
- OMCL $1,149,529,000.00
- Revenue This Year
- RCUS N/A
- OMCL $5.37
- Revenue Next Year
- RCUS N/A
- OMCL $3.67
- P/E Ratio
- RCUS N/A
- OMCL $63.63
- Revenue Growth
- RCUS 6.07
- OMCL 6.39
- 52 Week Low
- RCUS $6.50
- OMCL $22.66
- 52 Week High
- RCUS $18.98
- OMCL $55.75
- Technical
- Relative Strength Index (RSI)
- RCUS 66.27
- OMCL 45.32
- Support Level
- RCUS $11.30
- OMCL $31.73
- Resistance Level
- RCUS $12.05
- OMCL $33.32
- Average True Range (ATR)
- RCUS 0.58
- OMCL 0.97
- MACD
- RCUS 0.02
- OMCL -0.23
- Stochastic Oscillator
- RCUS 81.30
- OMCL 0.44
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
About OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.